Did You Know?

Editor’s Picks

Latest News

BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study

VANCOUVER, BC / ACCESS Newswire / September 8, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience...

Amwell Receives Frost & Sullivan’s 2026 United States Technology Innovation Leadership Recognition for Technology-Enabled Care Platforms

Amwell® is transforming virtual care delivery through its unified Amwell Platform, combining interoperability, clinical integration, and intelligent orchestration to improve...

error: Content is protected !!